JAZZ - Jazz Pharmaceuticals plc

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
http://www.jazzpharma.com

SectorHealthcare
IndustryBiotechnology
Full-time employees1,620

Key executives

NameTitlePayExercisedYear born
Mr. Bruce C. CozaddCo-Founder, Chairman & CEO1.97MN/A1964
Mr. Daniel N. Swisher Jr.Pres & COO1.15MN/A1963
Mr. Matthew P. YoungConsultant950.35k560.15k1969
Mr. Michael P. MillerExec. VP of US Commercial811.93kN/A1957
Ms. Renée D. GaláExec. VP & CFON/AN/A1973
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma. The company was founded in 2003 and is headquartered in Dublin, Ireland.

Corporate governance

Jazz Pharmaceuticals plc’s ISS governance QualityScore as of 4 December 2019 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.